Sodium-Glucose CoTransporter-2 Inhibitor Among Patients with Cancer Therapy-Induced Left Ventricular Dysfunction.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently been shown to improve clinical outcomes in patients with left ventricular (LV) dysfunction and heart failure (HF). Originally designed to induce glucosuria in diabetic patients by targeting sodium-glucose cotransporter (SGLT) proteins in the kidney, it has become evident that these drugs possess significant cardiovascular effects beyond their renal effects. However, the optimal application of SGLT-2i in cancer patients receiving cardiotoxic agents to mitigate the risk of adverse cardiac events remains uncertain.